Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Indian Firm Has Received CRL From FDA, Must Resolve Facility Observations
Executive Summary
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
You may also be interested in...
Three Filings Planned, Two Others On Track – But No Names From Viatris
Viatris’ CEO-in-waiting Scott Smith introduced himself during Viatris’ year-end earnings call.
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”